Australia markets closed

Cue Biopharma, Inc. (CUE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.9050+0.0050 (+0.26%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 92.67M
Enterprise value 58.85M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)15.88
Price/book (mrq)2.50
Enterprise value/revenue 10.72
Enterprise value/EBITDA -1.28

Trading information

Stock price history

Beta (5Y monthly) 2.01
52-week change 3-58.68%
S&P500 52-week change 323.57%
52-week high 35.1200
52-week low 31.3030
50-day moving average 31.8492
200-day moving average 32.4752

Share statistics

Avg vol (3-month) 3282.6k
Avg vol (10-day) 3347.31k
Shares outstanding 548.64M
Implied shares outstanding 648.64M
Float 845.38M
% held by insiders 12.97%
% held by institutions 132.89%
Shares short (15 Apr 2024) 44.78M
Short ratio (15 Apr 2024) 417.99
Short % of float (15 Apr 2024) 410.12%
Short % of shares outstanding (15 Apr 2024) 49.82%
Shares short (prior month 15 Mar 2024) 44.12M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-750.96%

Management effectiveness

Return on assets (ttm)-42.53%
Return on equity (ttm)-98.73%

Income statement

Revenue (ttm)5.49M
Revenue per share (ttm)0.12
Quarterly revenue growth (yoy)1,106.00%
Gross profit (ttm)N/A
EBITDA -51.44M
Net income avi to common (ttm)-50.73M
Diluted EPS (ttm)-1.1100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)48.51M
Total cash per share (mrq)1
Total debt (mrq)14.7M
Total debt/equity (mrq)39.63%
Current ratio (mrq)3.01
Book value per share (mrq)0.79

Cash flow statement

Operating cash flow (ttm)-39.96M
Levered free cash flow (ttm)-20.2M